|
PDCD1LG2
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Immunohistochemistry was performed for evaluation of tumor and immune cell infiltration for expression of PD-1, PD-L1, and PD-L2.
|
31593039 |
2020 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Membrane PD-L2 expression and cytoplasmic IDO1 expression were defined by tumor proportion score (TPS); samples with TPS < 1% were considered negative.
|
31163080 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Since ligands of the Programmed Death Receptor-1 (PD-L1 and PD-L2) play a crucial role within the tumor microenvironment for tumorigenesis, we investigated levels of sPD-L1 and sPD-L2 in liquid biopsies of serum samples, and correlated the results with the clinical status, presence of circulating tumor cells (CTCs) and disease outcome in primary EOC patients.
|
31681568 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Adrenocortical carcinoma samples were more likely to express programmed death ligand 2 on tumor cells or in stromal tissues than benign samples (OR = 2.3, P = .03).
|
30413322 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
In contrast, PD-L1 and PD-L2 did not correlate with clinical outcome while tumor β-catenin overexpression showed association with lower probability of response (OR 0.48, 95% CI 0.21-1.06, p = 0.068).
|
31730502 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Tumor expression of PD-L1 and PD-L2 was present on the cell membranes.
|
30633894 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Low programmed death-ligand 2 (PD-L2) was the most sensitive/specific marker to segregate patients with adverse outcomes; therefore, PD-L2 expression was chosen to distinguish immune infiltration<sup>HI</sup> (ie, high PD-L2) FL biopsies from immune infiltration<sup>LO</sup> (ie, low PD-L2) tumors.
|
31461379 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
In clinical settings, antitumor immune responses were significantly correlated with PD-L2 expression in the tumor microenvironment in renal cell carcinoma (RCC) and lung squamous cell carcinoma (LUSC).
|
31076547 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
High expression of PD-L2 on tumor membranes and PD-L1 in immune stroma were both significantly associated with poorer overall survival (OS) and disease-free survival (DFS) outcomes.
|
31572677 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Next-generation sequencing-based parameters include tumor mutation burden (TMB) and genomic amplification of PD-L1/PD-L2/JAK2 at 9p24.1.
|
30236595 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Using immunohistochemical staining with 28-8 and D7U8C Abs, the tumor proportion score was assessed for programmed cell death-1 ligand-1 (PD-L1), as high (50% or more) or low (less than 50%), and ligand-2 (PD-L2) expression, respectively.
|
31368625 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
The current study used a dataset downloaded from The Cancer Genome Atlas (TCGA) as well as 219 clinical tissue samples to investigate the infiltrating grade of cluster of differentiation (CD) 4 and CD8 tumor infiltrating lymphocytes (TILs), the expression levels of PD-L1 and PD-L2, the interferon-γ (IFN-γ) and CD8 T effector gene signatures, and the phosphorylated signal transducer and activator of transcription 1 (p-STAT1) status in patients with pMMR/MSI-L/MSS-CRC and dMMR/MSI-H-CRC.
|
31788072 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
The circulating levels of cytokines, chemokines, programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and PD-L2 were correlated with response, tumor PD-L1 expression, and other clinicopathological features.
|
31251403 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Known as co-stimulatory molecule, programmed death ligand-2 (PD-L2) contributes to T-cell exhaustion by interaction with programmed death-1 (PD-1) receptor, but its tumor cell-intrinsic signal effects have been little investigated.
|
30886151 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
FFPE sections were macrodissected to enrich for tumor for quantitative assessment of CD274 (PD-L1), PDCD1LG2 (PD-L2), CD8A, and IRF1 by RT-qPCR multiplex mRNA panel.
|
31533832 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
There was also a significant correlation between high Immunoscore and I-PD-L2, but not T-PD-L2 (<i>P</i> < 0.001 and <i>P</i> = 0.190, respectively).
|
31337259 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Programmed death 1 (PD-1), when activated by its ligands PD-L1 and PD-L2, suppresses active immune cells in normal immune regulation to limit autoimmunity and, in tumors, as a mechanism of immune evasion.
|
31086024 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Our work highlighted PD-L2 as a promising immunotherapeutic target with prognostic value combined with complex tumor infiltrating cells in PDAC.
|
31464648 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Low PD-L2 expression on tumor cells was statistically associated with histological type (non-keratinizing/keratinizing) and lymphatic invasion.
|
30815803 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Interferon-induced expression of programmed cell death ligands (PD-L1/PD-L2) may sustain tumour immune-evasion.
|
30723303 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
In 222 <sup>18</sup>F-FDG-PET/CT, the maximum standardized uptake value was significantly higher in patients with PD-L2-positive compared to those with PD-L2-negative tumors.
|
30348714 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
In contrast with this positive regulation of TAM recruitment, we found no evidence of a direct effect of ERK1/2 signaling on two other important aspects of TAM regulation by GBM cells: (1) the expression of the immune checkpoint ligands PD-L1 and PD-L2, expressed at high mRNA levels in GBM compared with other solid tumors; (2) the production of the tumor metabolite lactate recently reported to dampen tumor immunity by interacting with the receptor GPR65 present on the surface of TAM.
|
31467175 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The expression levels of CD68<sup>+</sup> tumor-associated macrophages (TAMs) and CD8<sup>+</sup> tumor-infiltrating lymphocytes (TILs), as well as the immune checkpoint molecules PD-1, PD-L1 and PD-L2 in stroma and in tumor regions were analyzed by immunohistochemistry (IHC).
|
31654628 |
2019 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
PD-L2 expression by tumor cells was not observed in the 24 cases without 9p24.1 rearrangement.
|
29112015 |
2018 |
|
PDCD1LG2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Immune checkpoint inhibitors have led to a breakthrough in solid tumor immunotherapy, but related studies on musculoskeletal tumors are few, especially for PD-L2.
|
29409495 |
2018 |